HIV-RNA VIRAL LOAD REDUCTION OF .5 LOG IS PREDICTIVE OF CLINICAL BENEFIT -- FDA ADVISORY CMTE.; FUTURE OF HIV TREATMENT IS INDIVIDUALIZING THERAPY -- FDA's FEIGAL
A .5 log reduction in HIV-RNA viral load is an acceptable indicator of virologic response in clinical trials of experimental HIV drugs, FDA's Antiviral Drugs Advisory Committee agreed at its July 14-15 meeting.
You may also be interested in...
FDA is encouraging sponsors of HIV therapies to conduct more clinical trials in treatment-experienced patients
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011